<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01149096</url>
  </required_header>
  <id_info>
    <org_study_id>ASCT0631D</org_study_id>
    <secondary_id>NCI-2011-02237</secondary_id>
    <secondary_id>CDR0000675536</secondary_id>
    <secondary_id>COG-ASCT0631D</secondary_id>
    <secondary_id>ASCT0631D</secondary_id>
    <secondary_id>ASCT0631D</secondary_id>
    <secondary_id>U10CA098543</secondary_id>
    <nct_id>NCT01149096</nct_id>
  </id_info>
  <brief_title>Collection of Bone Marrow From Donors Treated With or Without Filgrastim</brief_title>
  <official_title>A Comparison of Acute and Long-term Toxicities in Bone Marrow Donors With and Without G-CSF Treatment Prior to Harvest: A Companion Study to ASCT0631</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized clinical trial is studying the side effects of collection of bone marrow from
      donors treated with or without filgrastim. Giving colony-stimulating factors, such as
      filgrastim (G-CSF), to donors helps the stem cells move from the bone marrow to the blood so
      they can be collected and stored.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate short- and long-term toxicities in bone marrow donors treated with vs without
      filgrastim before harvest.

      II. To compare 10-year mortality and cancer in donors treated with vs without filgrastim.

      SECONDARY OBJECTIVES:

      I. To correlate the incidence of acute and chronic graft-vs-host disease in the marrow
      recipients enrolled on COG-ASCT0631 with four parameters assessed in the bone marrow
      harvests: absolute T-cell numbers, Th1 vs Th2 profile of T-cells, dendritic cell populations,
      and T-regulatory cell content.

      OUTLINE: Donors are randomized to 1 of 2 treatment arms.

      ARM I (unstimulated harvest): Donors undergo conventional (i.e., unstimulated) bone marrow
      harvest on day 0.

      ARM II (stimulated harvest): Donors receive filgrastim subcutaneously on days -4 through 0.
      Donors then undergo bone marrow harvest on day 0.

      After completion of study treatment, donors are followed up at 1, 6, and 12 months and then
      annually for up to 10 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2010</start_date>
  <completion_date type="Actual">September 30, 2016</completion_date>
  <primary_completion_date type="Actual">December 14, 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Short-term Adverse Events in G-CSF (Filgrastim) Stimulated Bone Marrow (G-BM) Donors</measure>
    <time_frame>Up to 1 year after donation</time_frame>
    <description>The Kaplan-Meier method will be used to estimate the cumulative incidence of short term adverse events defined by having any of the following events: 1) death due to a cause that is unknown or possibly related to G-CSF, 2) development of a malignancy, 3) development of a splenic rupture, or 4) development of a severe acute lung injury possibly related to GCSF therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced Death in G-CSF Stimulated-bone Marrow (G-BM) Donors</measure>
    <time_frame>Up to 1 year after donation</time_frame>
    <description>The Kaplan-Meier method will be used to estimate the cumulative incidence of death event in G-BM donors only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Grade 1 or 2 Toxicities</measure>
    <time_frame>Up to 1 year after donation</time_frame>
    <description>Estimate the percentage of patients having non-fatal complications of CTCAE Grades 1 or 2 in standard BM and G-CSF stimulated-bone marrow (G-BM) donors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Grade 3 or 4 Toxicities</measure>
    <time_frame>Up to 1 year after donation</time_frame>
    <description>Estimate the percentage of patients having non-fatal complications of Grade 3 other than pain (consider Grade 4 for pain only), or any of Grade 4 in standard BM and G-CSF stimulated-bone marrow (G-BM) donors. Modified Toxicity Criteria and Pain Assessment was used with higher grades corresponding to more severe AEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>10-year Mortality Rate in Marrow Donors</measure>
    <time_frame>Up to 10 years post bone marrow harvest</time_frame>
    <description>The Kaplan-Meier method will be used to estimate overall survival probabilities in standard BM and G-BM donors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>10-year Overall Cancer Incidence</measure>
    <time_frame>Up to 10 years post bone marrow harvest</time_frame>
    <description>The Kaplan-Meier method will be used to estimate overall cancer free probabilities in standard BM and G-BM donors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>10-year Hematologic Cancer Rate</measure>
    <time_frame>Up to 10 years post bone marrow harvest</time_frame>
    <description>The Kaplan-Meier method will be used to estimate hematologic cancer probabilities in standard BM and G-BM donors.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute T Cell Numbers</measure>
    <time_frame>Up to 1 year after donation</time_frame>
    <description>Median and interquartile range of the outcome measure in standard BM and G-BM donors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Th1 vs. Th2 Profile of T Cells</measure>
    <time_frame>Up to 1 year after donation</time_frame>
    <description>Proportion of donors with Th1-T cell profile in standard BM and G-BM donors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dendritic Cell (DC) Populations</measure>
    <time_frame>Up to 1 year after donation</time_frame>
    <description>Median and interquartile range of the outcome measure in standard BM and G-BM donors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T Regulatory Cell Content</measure>
    <time_frame>Up to 1 year after donation</time_frame>
    <description>Median and interquartile range of the outcome measure in standard BM and G-BM donors.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Healthy Stem Cell Donor</condition>
  <condition>No Evidence of Disease</condition>
  <arm_group>
    <arm_group_label>Arm I (conventional bone marrow harvest)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Donors undergo conventional (i.e., unstimulated) bone marrow harvest on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (filgrastim, bone marrow harvest)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donors receive filgrastim subcutaneously on days -4 through 0. Donors then undergo bone marrow harvest on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone Marrow Donation</intervention_name>
    <description>Undergo bone marrow harvest</description>
    <arm_group_label>Arm I (conventional bone marrow harvest)</arm_group_label>
    <arm_group_label>Arm II (filgrastim, bone marrow harvest)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>Arm II (filgrastim, bone marrow harvest)</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>Recombinant Methionyl Human Granulocyte Colony Stimulating Factor</other_name>
    <other_name>rG-CSF</other_name>
    <other_name>Tevagrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Optional correlative studies</description>
    <arm_group_label>Arm I (conventional bone marrow harvest)</arm_group_label>
    <arm_group_label>Arm II (filgrastim, bone marrow harvest)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Appropriately human leukocyte antigen (HLA)-matched (HLA, A, B, DRB1 identical or
             antigen mismatched [i.e., 5/6 or 6/6 antigens matched]) sibling of the bone marrow
             recipient enrolled on COG-ASCT0631

          -  Adequate size relative to the recipient (i.e., harvesting the maximum of 20 cc/kg from
             the donor would result in a bone marrow graft that will provide an adequate cell and
             volume dose to the recipient, in the opinion of the treating physician)

          -  Enrolled on the COG Umbrella Long-Term Follow-Up Study COG-ALTE05N1

          -  Not pregnant or nursing

          -  No human immunodeficiency virus (HIV) positivity

          -  No sickle cell trait or sickle cell anemia/disease

          -  Not at an increased risk from bone marrow donation after filgrastim administration due
             to a pre-existing medical condition, as determined by an independent physician
             separate from the research team

          -  None of the following:

               -  Active infection, especially pulmonary

               -  Splenomegaly or a history of splenic injury

               -  Active or recent pulmonary disease (i.e., pneumonia within the past 4 weeks)

               -  A condition that would make the donor unsuitable to donate, as determined by an
                  independent physician separate from the research team

          -  No autoimmune disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan A Grupp</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Medical Center-Parnassus</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital-Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University/Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Children's Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C S Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospitals and Clinics</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Childrens Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Oncology Group</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University/Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 22, 2010</study_first_submitted>
  <study_first_submitted_qc>June 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2010</study_first_posted>
  <results_first_submitted>December 18, 2019</results_first_submitted>
  <results_first_submitted_qc>February 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 26, 2020</results_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Conventional Bone Marrow Harvest)</title>
          <description>Donors undergo conventional (i.e., unstimulated) bone marrow harvest on day 0.
Bone Marrow Donation: Undergo bone marrow harvest
Laboratory Biomarker Analysis: Optional correlative studies</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Filgrastim, Bone Marrow Harvest)</title>
          <description>Donors receive filgrastim subcutaneously on days -4 through 0. Donors then undergo bone marrow harvest on day 0.
Bone Marrow Donation: Undergo bone marrow harvest
Filgrastim: Given subcutaneously
Laboratory Biomarker Analysis: Optional correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Conventional Bone Marrow Harvest)</title>
          <description>Donors undergo conventional (i.e., unstimulated) bone marrow harvest on day 0.
Bone Marrow Donation: Undergo bone marrow harvest
Laboratory Biomarker Analysis: Optional correlative studies</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Filgrastim, Bone Marrow Harvest)</title>
          <description>Donors receive filgrastim subcutaneously on days -4 through 0. Donors then undergo bone marrow harvest on day 0.
Bone Marrow Donation: Undergo bone marrow harvest
Filgrastim: Given subcutaneously
Laboratory Biomarker Analysis: Optional correlative studies</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.5" spread="5.2"/>
                    <measurement group_id="B2" value="14.4" spread="5.9"/>
                    <measurement group_id="B3" value="10.8" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Short-term Adverse Events in G-CSF (Filgrastim) Stimulated Bone Marrow (G-BM) Donors</title>
        <description>The Kaplan-Meier method will be used to estimate the cumulative incidence of short term adverse events defined by having any of the following events: 1) death due to a cause that is unknown or possibly related to G-CSF, 2) development of a malignancy, 3) development of a splenic rupture, or 4) development of a severe acute lung injury possibly related to GCSF therapy.</description>
        <time_frame>Up to 1 year after donation</time_frame>
        <population>Analysis conducted within G-BM donors only, therefore, no report for the control arm (Conventional bone marrow transplant).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm II (Filgrastim, Bone Marrow Harvest)</title>
            <description>Donors receive filgrastim subcutaneously on days -4 through 0. Donors then undergo bone marrow harvest on day 0.
Bone Marrow Donation: Undergo bone marrow harvest
Filgrastim: Given subcutaneously
Laboratory Biomarker Analysis: Optional correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Short-term Adverse Events in G-CSF (Filgrastim) Stimulated Bone Marrow (G-BM) Donors</title>
          <description>The Kaplan-Meier method will be used to estimate the cumulative incidence of short term adverse events defined by having any of the following events: 1) death due to a cause that is unknown or possibly related to G-CSF, 2) development of a malignancy, 3) development of a splenic rupture, or 4) development of a severe acute lung injury possibly related to GCSF therapy.</description>
          <population>Analysis conducted within G-BM donors only, therefore, no report for the control arm (Conventional bone marrow transplant).</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced Death in G-CSF Stimulated-bone Marrow (G-BM) Donors</title>
        <description>The Kaplan-Meier method will be used to estimate the cumulative incidence of death event in G-BM donors only.</description>
        <time_frame>Up to 1 year after donation</time_frame>
        <population>Analysis conducted for stimulated-bone marrow (G-BM) donors only, therefore, no report on the control arm (Conventional bone marrow transplant).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm II (Filgrastim, Bone Marrow Harvest)</title>
            <description>Donors receive filgrastim subcutaneously on days -4 through 0. Donors then undergo bone marrow harvest on day 0.
Bone Marrow Donation: Undergo bone marrow harvest
Filgrastim: Given subcutaneously
Laboratory Biomarker Analysis: Optional correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Death in G-CSF Stimulated-bone Marrow (G-BM) Donors</title>
          <description>The Kaplan-Meier method will be used to estimate the cumulative incidence of death event in G-BM donors only.</description>
          <population>Analysis conducted for stimulated-bone marrow (G-BM) donors only, therefore, no report on the control arm (Conventional bone marrow transplant).</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Grade 1 or 2 Toxicities</title>
        <description>Estimate the percentage of patients having non-fatal complications of CTCAE Grades 1 or 2 in standard BM and G-CSF stimulated-bone marrow (G-BM) donors.</description>
        <time_frame>Up to 1 year after donation</time_frame>
        <population>Modified Toxicity Criteria and Pain Assessment was used with higher grades corresponding to more severe AEs.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Conventional Bone Marrow Harvest)</title>
            <description>Donors undergo conventional (i.e., unstimulated) bone marrow harvest on day 0.
Bone Marrow Donation: Undergo bone marrow harvest
Laboratory Biomarker Analysis: Optional correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Filgrastim, Bone Marrow Harvest)</title>
            <description>Donors receive filgrastim subcutaneously on days -4 through 0. Donors then undergo bone marrow harvest on day 0.
Bone Marrow Donation: Undergo bone marrow harvest
Filgrastim: Given subcutaneously
Laboratory Biomarker Analysis: Optional correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Grade 1 or 2 Toxicities</title>
          <description>Estimate the percentage of patients having non-fatal complications of CTCAE Grades 1 or 2 in standard BM and G-CSF stimulated-bone marrow (G-BM) donors.</description>
          <population>Modified Toxicity Criteria and Pain Assessment was used with higher grades corresponding to more severe AEs.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Grade 3 or 4 Toxicities</title>
        <description>Estimate the percentage of patients having non-fatal complications of Grade 3 other than pain (consider Grade 4 for pain only), or any of Grade 4 in standard BM and G-CSF stimulated-bone marrow (G-BM) donors. Modified Toxicity Criteria and Pain Assessment was used with higher grades corresponding to more severe AEs.</description>
        <time_frame>Up to 1 year after donation</time_frame>
        <population>All patients included in analysis. No incidence of grades 3 or 4 toxicities.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Conventional Bone Marrow Harvest)</title>
            <description>Donors undergo conventional (i.e., unstimulated) bone marrow harvest on day 0.
Bone Marrow Donation: Undergo bone marrow harvest
Laboratory Biomarker Analysis: Optional correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Filgrastim, Bone Marrow Harvest)</title>
            <description>Donors receive filgrastim subcutaneously on days -4 through 0. Donors then undergo bone marrow harvest on day 0.
Bone Marrow Donation: Undergo bone marrow harvest
Filgrastim: Given subcutaneously
Laboratory Biomarker Analysis: Optional correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Grade 3 or 4 Toxicities</title>
          <description>Estimate the percentage of patients having non-fatal complications of Grade 3 other than pain (consider Grade 4 for pain only), or any of Grade 4 in standard BM and G-CSF stimulated-bone marrow (G-BM) donors. Modified Toxicity Criteria and Pain Assessment was used with higher grades corresponding to more severe AEs.</description>
          <population>All patients included in analysis. No incidence of grades 3 or 4 toxicities.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>10-year Mortality Rate in Marrow Donors</title>
        <description>The Kaplan-Meier method will be used to estimate overall survival probabilities in standard BM and G-BM donors.</description>
        <time_frame>Up to 10 years post bone marrow harvest</time_frame>
        <population>Data were not collected as no patients were followed to 10 years.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Conventional Bone Marrow Harvest)</title>
            <description>Donors undergo conventional (i.e., unstimulated) bone marrow harvest on day 0.
Bone Marrow Donation: Undergo bone marrow harvest
Laboratory Biomarker Analysis: Optional correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Filgrastim, Bone Marrow Harvest)</title>
            <description>Donors receive filgrastim subcutaneously on days -4 through 0. Donors then undergo bone marrow harvest on day 0.
Bone Marrow Donation: Undergo bone marrow harvest
Filgrastim: Given subcutaneously
Laboratory Biomarker Analysis: Optional correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>10-year Mortality Rate in Marrow Donors</title>
          <description>The Kaplan-Meier method will be used to estimate overall survival probabilities in standard BM and G-BM donors.</description>
          <population>Data were not collected as no patients were followed to 10 years.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>10-year Overall Cancer Incidence</title>
        <description>The Kaplan-Meier method will be used to estimate overall cancer free probabilities in standard BM and G-BM donors.</description>
        <time_frame>Up to 10 years post bone marrow harvest</time_frame>
        <population>Data were not collected as no patients were followed to 10 years.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Conventional Bone Marrow Harvest)</title>
            <description>Donors undergo conventional (i.e., unstimulated) bone marrow harvest on day 0.
Bone Marrow Donation: Undergo bone marrow harvest
Laboratory Biomarker Analysis: Optional correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Filgrastim, Bone Marrow Harvest)</title>
            <description>Donors receive filgrastim subcutaneously on days -4 through 0. Donors then undergo bone marrow harvest on day 0.
Bone Marrow Donation: Undergo bone marrow harvest
Filgrastim: Given subcutaneously
Laboratory Biomarker Analysis: Optional correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>10-year Overall Cancer Incidence</title>
          <description>The Kaplan-Meier method will be used to estimate overall cancer free probabilities in standard BM and G-BM donors.</description>
          <population>Data were not collected as no patients were followed to 10 years.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>10-year Hematologic Cancer Rate</title>
        <description>The Kaplan-Meier method will be used to estimate hematologic cancer probabilities in standard BM and G-BM donors.</description>
        <time_frame>Up to 10 years post bone marrow harvest</time_frame>
        <population>Data were not collected as no patients were followed to 10 years.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Conventional Bone Marrow Harvest)</title>
            <description>Donors undergo conventional (i.e., unstimulated) bone marrow harvest on day 0.
Bone Marrow Donation: Undergo bone marrow harvest
Laboratory Biomarker Analysis: Optional correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Filgrastim, Bone Marrow Harvest)</title>
            <description>Donors receive filgrastim subcutaneously on days -4 through 0. Donors then undergo bone marrow harvest on day 0.
Bone Marrow Donation: Undergo bone marrow harvest
Filgrastim: Given subcutaneously
Laboratory Biomarker Analysis: Optional correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>10-year Hematologic Cancer Rate</title>
          <description>The Kaplan-Meier method will be used to estimate hematologic cancer probabilities in standard BM and G-BM donors.</description>
          <population>Data were not collected as no patients were followed to 10 years.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute T Cell Numbers</title>
        <description>Median and interquartile range of the outcome measure in standard BM and G-BM donors.</description>
        <time_frame>Up to 1 year after donation</time_frame>
        <population>Data were not collected for this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Conventional Bone Marrow Harvest)</title>
            <description>Donors undergo conventional (i.e., unstimulated) bone marrow harvest on day 0.
Bone Marrow Donation: Undergo bone marrow harvest
Laboratory Biomarker Analysis: Optional correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Filgrastim, Bone Marrow Harvest)</title>
            <description>Donors receive filgrastim subcutaneously on days -4 through 0. Donors then undergo bone marrow harvest on day 0.
Bone Marrow Donation: Undergo bone marrow harvest
Filgrastim: Given subcutaneously
Laboratory Biomarker Analysis: Optional correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute T Cell Numbers</title>
          <description>Median and interquartile range of the outcome measure in standard BM and G-BM donors.</description>
          <population>Data were not collected for this study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Th1 vs. Th2 Profile of T Cells</title>
        <description>Proportion of donors with Th1-T cell profile in standard BM and G-BM donors.</description>
        <time_frame>Up to 1 year after donation</time_frame>
        <population>Data were not collected for this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Conventional Bone Marrow Harvest)</title>
            <description>Donors undergo conventional (i.e., unstimulated) bone marrow harvest on day 0.
Bone Marrow Donation: Undergo bone marrow harvest
Laboratory Biomarker Analysis: Optional correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Filgrastim, Bone Marrow Harvest)</title>
            <description>Donors receive filgrastim subcutaneously on days -4 through 0. Donors then undergo bone marrow harvest on day 0.
Bone Marrow Donation: Undergo bone marrow harvest
Filgrastim: Given subcutaneously
Laboratory Biomarker Analysis: Optional correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Th1 vs. Th2 Profile of T Cells</title>
          <description>Proportion of donors with Th1-T cell profile in standard BM and G-BM donors.</description>
          <population>Data were not collected for this study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dendritic Cell (DC) Populations</title>
        <description>Median and interquartile range of the outcome measure in standard BM and G-BM donors.</description>
        <time_frame>Up to 1 year after donation</time_frame>
        <population>Data were not collected for this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Conventional Bone Marrow Harvest)</title>
            <description>Donors undergo conventional (i.e., unstimulated) bone marrow harvest on day 0.
Bone Marrow Donation: Undergo bone marrow harvest
Laboratory Biomarker Analysis: Optional correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Filgrastim, Bone Marrow Harvest)</title>
            <description>Donors receive filgrastim subcutaneously on days -4 through 0. Donors then undergo bone marrow harvest on day 0.
Bone Marrow Donation: Undergo bone marrow harvest
Filgrastim: Given subcutaneously
Laboratory Biomarker Analysis: Optional correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Dendritic Cell (DC) Populations</title>
          <description>Median and interquartile range of the outcome measure in standard BM and G-BM donors.</description>
          <population>Data were not collected for this study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T Regulatory Cell Content</title>
        <description>Median and interquartile range of the outcome measure in standard BM and G-BM donors.</description>
        <time_frame>Up to 1 year after donation</time_frame>
        <population>Data were not collected for this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Conventional Bone Marrow Harvest)</title>
            <description>Donors undergo conventional (i.e., unstimulated) bone marrow harvest on day 0.
Bone Marrow Donation: Undergo bone marrow harvest
Laboratory Biomarker Analysis: Optional correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Filgrastim, Bone Marrow Harvest)</title>
            <description>Donors receive filgrastim subcutaneously on days -4 through 0. Donors then undergo bone marrow harvest on day 0.
Bone Marrow Donation: Undergo bone marrow harvest
Filgrastim: Given subcutaneously
Laboratory Biomarker Analysis: Optional correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>T Regulatory Cell Content</title>
          <description>Median and interquartile range of the outcome measure in standard BM and G-BM donors.</description>
          <population>Data were not collected for this study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First year after Bone Marrow Harvest</time_frame>
      <desc>Modified Toxicity Criteria and Pain Assessment was used with higher grades corresponding to more severe AEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Conventional Bone Marrow Harvest)</title>
          <description>Donors undergo conventional (i.e., unstimulated) bone marrow harvest on day 0.
Bone Marrow Donation: Undergo bone marrow harvest
Laboratory Biomarker Analysis: Optional correlative studies</description>
        </group>
        <group group_id="E2">
          <title>Arm II (Filgrastim, Bone Marrow Harvest)</title>
          <description>Donors receive filgrastim subcutaneously on days -4 through 0. Donors then undergo bone marrow harvest on day 0.
Bone Marrow Donation: Undergo bone marrow harvest
Filgrastim: Given subcutaneously
Laboratory Biomarker Analysis: Optional correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Bones (Including Sternum and Ribs) pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dizziness, vertigo, or lightheadedness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fever in the absence of infections</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hip pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>IV Site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Insomnia (Inability to sleep)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Joints (Excluding hip) pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Limbs (Arm, legs, hands feet) pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Loss of Appetite (Anorexia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Muscles pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Other pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rashes on skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Throat pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Must obtain prior approval.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Results Reporting Coordinator</name_or_title>
      <organization>Children's Oncology Group</organization>
      <phone>626-447-0064</phone>
      <email>resultsreportingcoordinator@childrensoncologygroup.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

